1. Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy. (3rd July 2018) Authors: Xipell, M.; Victoria, I.; Hoffmann, V.; Villarreal, J.; García-Herrera, A.; Reig, O.; Rodas, L.; Blasco, M.; Poch, E.; Mellado, B.; Quintana, L. F. Journal: Oncoimmunology Issue: Volume 7:Number 7(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗